Abstract
Hereditary angioedema is a rare disorder associated with recurrent episodes of swellings in different body areas. C1 inhibitor deficiency is the most common cause of this disease.
Bradykinin is considered to be the main mediator responsible for angioedema formation. Fully human monoclonal antibody lanadelumab targets plasma kalikrein, which is responsible for bradykinin formation.
It is currently registered for long term prophylaxis in hereditary angioedema and represents a highly effective and well tolerated treatment option in patients with frequent and severe swellings.